Generic Name and Formulations:
Ketamine HCl 10mg/mL, 50mg/mL, 100mg/mL; soln for IM or IV inj.
Par Pharmaceutical, Inc.
Indications for KETALAR:
Sole anesthetic agent for diagnostic and surgical procedures not requiring skeletal muscle relaxation. Induction prior to other general anesthesia. Supplement to low-potency agents (eg, nitrous oxide).
Adults and Children:
<16yrs: not established. Pretreat with atropine, scopolamine or other drying agent prior to induction. Individualize. Give by slow IV inj over 60secs. ≥16yrs: IV induction: initial range: 1–4.5mg/kg; usually 2mg/kg to produce 5–10mins surgical anesthesia. Alternatively, 1–2mg/kg at rate of 0.5mg/kg/min may be used. In addition, diazepam 2–5mg doses given in separate syringe over 60 secs, may be used. IM induction: initial range: 6.5–13mg/kg; usually 10mg/kg to produce 12–25mins surgical anesthesia. Usual range: 9–13mg/kg IM to produce surgical anesthesia within 3–4mins following inj, with effects lasting 12–25mins. Maintenance: repeat as needed in increments of 1/2 to full induction dose; see full labeling. Supplementary to nitrous oxide/oxygen: use reduced ketamine dose with diazepam.
To be administered under the supervision of experienced clinicians. Have resuscitative equipment available. Avoid monotherapy and/or mechanical stimulation in pharynx, larynx or bronchial tree surgery/diagnostic procedures; may require muscle relaxants. Hypertensive or cardiac decompensated; monitor cardiac function. Monitor for psychological manifestations post-op. Preanesthetic elevated cerebrospinal fluid pressure. Alcoholics, drug abusers. Abuse potential. Pediatric neurotoxicity risk with repeated or prolonged use. Elderly. Labor and delivery, pregnancy: not recommended.
Concomitant barbiturates and/or narcotics may prolong recovery time.
NMDA receptor antagonist.
Hyper or hypotension, bradycardia, arrhythmia, respiratory depression (may be severe; esp. with rapid IV or high-doses), apnea, laryngospasms, airway obstruction, diplopia, nystagmus, intraocular pressure, tonic/clonic movements, anorexia, GI upset, anaphylaxis, inj site pain, exanthema, transient erythema, rash; emergence reactions (eg, pleasant dream-like states, hallucinations, delirium, confusion, excitement, irrational behavior), elevated cerebrospinal fluid pressure.
Multi-dose vials (5mL, 10mL, 20mL)—10
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|